deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04304040

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

A Phase I/IIa Study on Dose-escalation and Extension of Recombinant Humanized Type II CD20 Monoclonal Antibody MIL62 Injection Combined With BTK Inhibitor Orelabrutinib in the Treatment of Recurrent/Refractory CD20+B-cell Lymphoma

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Conditions B-cell Lymphoma Recurrent B-cell Lymphoma Refractory
Interventions Orelabrutinib Recombinant humanized monoclonal antibody MIL62 injection
Updated 9 times since 2020 Last updated: Feb 5, 2024 Started: Jul 28, 2020 Primary completion: Dec 30, 2025 Completion: Dec 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates B-cell Lymphoma Recurrent and B-cell Lymphoma Refractory and is currently ongoing. Beijing InnoCare Pharma Tech Co., Ltd. leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshotNot Yet Recruiting~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotNot Yet Recruiting~Sep 2021 – ~Dec 2022 · 15 months · monthly snapshotRecruiting~Dec 2022 – ~Mar 2024 · 15 months · monthly snapshotActive Not Recruiting~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2026 · 18 months · monthly snapshotActive Not Recruiting~Mar 2026 – present · 4 months · monthly snapshot

Change History

9 versions recorded

  1. Mar 2026 — Present [monthly]

    Unknown PHASE1/PHASE2

    Status: Active Not Recruiting → Unknown

  2. Sep 2024 — Mar 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Dec 2022 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 4 earlier versions

  1. Sep 2021 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  2. Jan 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  3. Jul 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  4. Apr 2020 — Jul 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beijing InnoCare Pharma Tech Co., Ltd.
Data source: Beijing InnoCare Pharma Tech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations